Psychemedics Corporation Boosts Quarterly Dividend Amount 20% (PMD)

By: ,


After paying a flat $0.15 dividend for the past 27 consecutive quarters, Psychemedics Corporation (NASDAQ:PMD) rewarded its shareholder with a 20% quarterly dividend boost and offers a 3.45% yield.


The company has paid the same $0.15 dividend distribution every quarter since the beginning of 2012. However, after a strong financial report that included record first-quarter revenue and 13% revenue growth versus the previous period, the company hiked its quarterly dividend payout for the first time since the fourth quarter of 2011.

In addition to the steady dividend income, the company contributed a moderate share-price increase to reward its shareholders with a double-digit-percentage total return during the past 12 months. The company will distribute its next dividend on its May 18, 2018, pay date to all its shareholders of record prior to its ex-dividend date on May 7, 2018.



Psychemedics Corporation (NASDAQ:PMD)

Headquartered in Acton, Massachusetts, and founded in 1985, the Psychemedics Corporation provides testing products and services for the detection of drug abuse through the analysis of hair samples in the United States and internationally. The drug tests provide quantitative information of the approximate amount of drug ingested, as well as historical data, which can show a pattern of individual drug use over a longer period. The company provides screening for cocaine, marijuana, Phencyclidine (PCP), amphetamines, synthetic cannabinoids and benzodiazepines, as well as opiates. Those opiates include heroin, hydrocodone, hydromorphone, oxycodone, oxymorphone and codeine. The company offers its services to employers for applicant and employee testing, treatment professionals, law enforcement agencies, school administrators, parents concerned about their children’s drug use, Fortune 500 companies and small to mid-size corporations, as well as school and government entities.

The company hiked its quarterly dividend payout 20% from the $0.15 amount to the current $0.18. Since the company already distributed one dividend installment of $0.15 in 2018 and the new, higher dividend amount will be paid only for the last three quarters, the total annual dividend amount in 2018 will be 15% higher than the total dividends paid in 2017.

The new quarterly payout amount of $0.18 corresponds to a $0.72 annualized total dividend and currently yields 3.45%. This current yield is 1.5% higher than the company’s own average yield of 3.4% over the past five years.


Psychemedics Corporation cut its annual dividend in 2009 and in 2010 following the 2008 financial crisis. However, despite hiking its annual dividend payout amount only seven times in the past 15 years, the company still managed to enhance its annual dividend amount 125% over that period, which is equivalent to an average growth rate of 5.6% per year.

The company currently has the 10th-highest yield among more than 80 major companies in the entire health care sector. Among the nine companies that have yields above Psychemedics Corporation’s current 3.45%, seven companies are drug manufacturers, which generally have dividends that are higher than sector averages. Even compared to the companies in the Drug Manufacturers market segment, Psychemedics Corporation’s current yield outperformed dividend yields of some drug manufacturing giants, such as Merck & Co., Inc. (NYSE:MRK), the Bristol-Myers Squibb Company (NYSE:BMY), Johnson & Johnson (NYSE:JNJ) and Eli Lilly & Company (NYSE:LLY).

Psychemedics Corporation’s 3.45% yield is nearly five times higher than the $0.73 simple average yield of all the companies in the overall health care sector. With the highest yield in the entire Medical Laboratories & Research market segment, Psychemedics Corporation’s current yield is 250% above the 0.98% average yield of all the companies in the segment and 74% higher than the 1.98% average yield of only dividend-paying companies in the group.

In addition to the steady dividend income, the company provided its investors with a long-term trend of asset appreciation. The company’s share price rose more than 43% at the beginning of the current 12-month period and reached its 52-week high of $27.15 on July 11, 2017. However, the share price reversed direction and fell nearly 40% by October 24, 2017, when it reached its 52-week low of $16.63. Since the October low, the share price regained 60% of that loss and closed on April 26, 2018, at $20.86, which was 10% higher than it was 12 months earlier, 25.4% above the October low and 86% higher than it was five years ago.

The dividend income distribution and the share-price growth combined to offer Psychemedics Corporation’s shareholders a one-year total return on investment of more than 13%. Additionally, the long-term investors enjoyed a 31.5% total return over the past three years and a total return of 120% over the last five years.


Dividend increases and dividend decreases, new dividend announcements, dividend suspensions and other dividend changes occur daily. To make sure you don’t miss any important announcements, sign up for our E-mail Alerts. Let us do the hard work of gathering the data and sending the relevant information directly to your inbox.

In addition to E-mail Alerts, you will have access to our powerful dividend research tools. Take a quick video tour of the tools suite.



Related Posts:

Ned Piplovic

Connect with Ned Piplovic

Ned Piplovic
Ned Piplovic, formerly an assistant editor of website content at Eagle Financial Publications, is an economic analyst and editor at Skousen Publishing. Additionally, Ned is also a teaching assistant at Chapman University to Mark Skousen, PhD, a free-market economist and Doti-Spogli Endowed Chair of Free Enterprise at the school. Ned graduated from Columbia University with a bachelor’s degree in Economics and Philosophy. He previously spent 15 years in corporate operations and financial management. Ned has written hundreds of articles for and
Search Dividend Investor